异基因造血干细胞移植治疗STAT3高IgE综合征:一项全球研究
这项国际多中心回顾性研究纳入41例接受造血干细胞移植的STAT3高IgE综合征患者,移植指征为感染(93%)或淋巴瘤(7%),中位随访5年,5年总生存率93%、无事件生存率90%,87%患者细菌或真菌呼吸道感染减少或消失,但20%患者移植后出现新发骨折。
要点
- 41例STAT3高IgE综合征患者接受造血干细胞移植,5年总生存率93%、无事件生存率90%。
- 移植前93%患者存在呼吸系统疾病,但移植后87%患者细菌或真菌呼吸道感染减少或消失。
- 移植后20%患者出现新发骨折,对免疫外表现的影响似乎有限。
核心结论
- 这项全球研究将STAT3高IgE综合征造血干细胞移植数据扩展至41例患者;尽管移植前肺部并发症显著,总生存率仍高,患者皮肤和呼吸系统疾病改善,但对免疫外表现的影响似乎有限。
研究设计与样本
- 国际多中心回顾性研究,纳入41例接受造血干细胞移植的STAT3高IgE综合征患者,研究跨28年。
主要发现
- 移植指征为感染(93%)或淋巴瘤(7%);移植时中位年龄14岁(范围4-45岁)。
- 移植前93%患者有呼吸系统疾病,包括肺实质疾病(68%)和既往疑似或确诊肺部真菌感染(32%)。
- 移植物来源为外周血干细胞(51%)或骨髓(49%);供者类型为HLA 10/10相合无关供者(44%)、相合家族供者(44%)、不合家族供者(10%)或1例9/10不合无关供者(2%)。
- 预处理方案以苏消安为基础(59%;其中34%联合塞替派),其他患者接受白消安为基础(24%)或美法仑为基础(17%)方案。
- 存活患者中位随访5年(范围0.8-28年);5年总生存率93%,5年无事件生存率90%;2至4级急性移植物抗宿主病累积发生率22%;最近随访时供者全血嵌合率中位数100%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Signal transduction and activator of transcription 3 hyperimmunoglobulin E syndrome (STAT3-HIES) is a multisystem disorder causing recurrent skin and respiratory infection with bronchiectasis, pneumatoceles, and aspergillosis; lymphoma; and extraimmune manifestations including fractures and vasculopathy. Published data on immune and extraimmune hematopoietic stem cell transplant (HSCT) outcomes focus on case reports or small cohorts. We conducted an international multicenter retrospective study of HSCT in STAT3-HIES. Primary end points were overall survival (OS) and event-free survival (EFS; events were death, graft failure, chronic graft-versus-host disease [GVHD]). We identified 41 patients over a 28-year period. HSCT indication was infection (93%) or lymphoma (7%). Median age at HSCT was 14 years (range, 4-45). Most patients had pre-HSCT respiratory disease (93%), including parenchymal lung disease (68%), and prior suspected/confirmed pulmonary fungal infection (32%). Patients received peripheral blood stem cells (51%) or marrow (49%) from HLA 10/10-matched unrelated donors (44%), matched family donors (44%), mismatched family donors (10%), or 1 9/10-mismatched unrelated donor (2%). Conditioning regimens were predominantly treosulfan-based (59%; with thiotepa, 34%); other patients received busulfan-based (24%) or melphalan-based (17%) regimens. Median follow-up for surviving patients was 5 years (0.8-28). The 5-year OS was 93%, and 5-year EFS 90%. Cumulative incidence of grade 2 to 4 acute GVHD was 22%. Median whole blood donor chimerism at latest follow-up was 100%. Eighty-seven percent of patients have reduced or no bacterial or fungal respiratory infection. After HSCT, 20% developed new skeletal fractures. This worldwide study expanded data on HSCT for STAT3-HIES to 41 patients; despite significant pre-HSCT pulmonary morbidity, OS was high, and patients have improved skin and respiratory disease though the impact on extraimmune manifestations appears limited.
引用
- Tsilifis C, Raedler J, Renke J, et al. Allogeneic hematopoietic stem cell transplantation for STAT3 hyper-IgE syndrome: a worldwide study. Blood Adv. 2025. PMID: 40540800. doi:10.1182/bloodadvances.2025016158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。